
Cheese Recall Over Potential Listeria Risk
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A New York-based cheese company has issued a recall of cases of brie over possible Listeria contamination, the Food and Drug Administration (FDA) announced on Thursday.
New York-based Fromi USA is recalling 12 cases of Brie Royal Faucon 1kg after being notified by a foreign manufacturer that its health authority had flagged the contamination risk.
Newsweek reached out to Fromi USA for comment via email outside of regular working hours.
Why it Matters
Listeria infection is the third leading cause of death from foodborne illness in the United States, according to the Centers for Disease Control and Prevention. Each year, an estimated 1,600 people are infected with Listeria, and 260 people die.
Listeria monocytogenes can be especially serious for pregnant women, newborns, adults 65 and older and people with weakened immune systems, the CDC said.
Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, infections can be fatal. Listeria infection can also cause miscarriages and stillbirths among pregnant women.
Stock image of brie cheese.
Stock image of brie cheese.
FRANCOIS GUILLOT/AFP via Getty Images
What To Know
The product impacted by the recall is:
12 cases of Brie Royal Faucon 1kg
The brie was distributed to Cheese Plate Park Slope LLC, located at 400 7th Avenue, 11215, Brooklyn, NY. It was then cut and sold to customers from Cheese Plate Brooklyn - Park Slope LLC, and Cheese Plate Brooklyn: Carroll Gardens from 07/24/2025 through 08/13/2025.
The cheese is made from pasteurized cow's milk and is packed 2 units/case. Each cheese is placed in a wooden box and is a bulk product that can be sold either whole or cut into portions. Lot number 615 appears on both the wooden box of each cheese and the case.
As of August 14, the FDA has reported no illnesses in the United States tied to the product.
What People Are Saying
The FDA, on Listeria: "Listeria monocytogenes (L. monocytogenes) is a type of disease-causing bacteria that can be found in many places, including soil, water, sewage, rotting vegetation, and animals. It can survive and grow even under refrigeration. L. monocytogenes can thrive in unsanitary food production conditions, leading to contamination of the food. When people eat food contaminated with L. monocytogenes, they may develop a disease called listeriosis.
"L. monocytogenes is generally transmitted when food is harvested, processed, prepared, packed, transported, or stored in manufacturing or production environments contaminated with L. monocytogenes. Environments can become contaminated by raw materials, water, soil, and incoming air. Pets can also spread the bacteria in the home if they eat food contaminated with L. monocytogenes."
What Happens Next
Consumers who have purchased The Brie Royal Faucon 1kg or cut portions are urged to return them to the place of purchase for a full refund.
Customers with questions can contact Fromi USA at (212) 583-4920 from 9 a.m. to 5 p.m. ET, Monday to Friday.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FDA Monitors Safety Issue with Boston Scientific Defibrillator Leads
Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced that it is monitoring a safety issue with Boston Scientific Corporation's ENDOTAK RELIANCE defibrillation leads, which are used with implantable cardioverter-defibrillators to prevent sudden cardiac death. Earlier this year, the company sent a letter to healthcare providers on July 24, warning that calcification of the leads' expanded polytetrafluoroethylene/ePTFE coating could lead to a gradual increase in low-voltage shock impedance/LVSI. This can reduce the effectiveness of life-saving shocks and even result in patient death. A surgeon examining a patient's brain in an operating room, paramedics nearby. The affected leads were manufactured and distributed between 2002 and 2021 and are no longer available. As of July 24, Boston Scientific had reported 386 serious injuries and 16 deaths linked to this issue. The FDA has categorized this as a potentially high-risk problem and is actively reviewing data to determine further regulatory action. Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It has 2 segments: MedSurg and Cardiovascular. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
What to Know TODAY: Woman Who Lost 240 Pounds Shares Question That Helped Her Eat Better
The Food and Drug Administration has issued an alert over certain cookware due to risk of lead leaching into food. Plus, a woman who dropped 240 pounds after taking up running shares her weight loss tips, and a dentist offers a simple trick to help you stop clenching your jaw. Here's what to know for Friday, Aug. 15, 2025. FDA Issues Alert Over Cookware Due to Risk of Lead Leaching Into Food Home cooks should take a close look at their pots, pans and kitchen utensils due to a risk of 'significant levels of lead' leaching into food, according to the U.S. Food and Drug Administration. The agency recently posted an alert regarding a Kada/Karahi Tiger White pure aluminum bowl because of associated health risks discovered during recent testing and shared which other products may be higher risk for leaching lead. Here's what to know. Woman Loses 240 Pounds. 1 Simple Question Helped Her Stop 'Eating Really Bad' Samantha Hager weighed nearly 380 pounds when she vowed to lose weight after visiting an amusement park with her stepsons and couldn't fit on the rides. She took up running — an activity she hated — and made changes to her diet, dropping 240 pounds in the process. Hager, 29, shares her tips for eating healthier, including the question she asked herself when she was tempted by junk food. Dentist Shares 1 Simple Breathing Exercise to Stop Clenching Your Jaw In Expert Tip of the Day, a dentist reveals how in less than a minute, you can relax your jaw muscles with this simple trick. Award-Winning Hair Tools for Combating Hair Loss, Styling Unruly Strands and More — Starting at $12 Shop TODAY's first-ever Hair Awards have landed! Staffers spent weeks curling, straightening, teasing and combing their hair to find the best tools. Consider these the best of the best. Chicken Parmesan Burgers These burgers from cookbook author Anna Francese Gass have all the flavors of a classic chicken Parm in a juicy sandwich. Since they're made on a sheet pan, cleanup is a breeze. Get the recipe! This article was originally published on


Business Insider
7 hours ago
- Business Insider
Tonix announces FDA approval of Tonmya for treatment of fibromyalgia
Tonix Pharmaceuticals (TNXP) Holding Corp. announced that the FDA approved Tonmya for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (greater than or equal to30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. Elevate Your Investing Strategy: